PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure at Inova
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Best Practice Advisory using Electronic Health Record.
- Who it may be relevant to
- Registry conditions: Heart Failure. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure (PROMPT-HF) at Inova
Overview
A randomized, single-blind intervention trial to test the comparative effectiveness of an electronic health record best practice advisory system that informs clinicians of guideline-indicated and FDA-approved heart failure medications currently not prescribed to their patients with heart failure versus usual care (no alert and how things are done currently). The purpose of the alert is to stimulate appropriate medication prescription for patients with heart failure and a reduced ejection fraction. This will be done across outpatient Inova clinics and at the five Inova hospitals.
Interventions
- Other Best Practice Advisory using Electronic Health Record
Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will
Primary outcome measures
- Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction [Time frame: 30 days after randomization]
Secondary outcome measures (4)
- All-cause hospitalization and all-cause mortality at 30 days [Time frame: 30 days]
- All-cause hospitalization and all-cause mortality at 90 days [Time frame: 90 days]
- All-cause hospitalization and all-cause mortality at 180 days [Time frame: 180 days]
- All-cause hospitalization and all-cause mortality at 1 year [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- Age>18 Years
- Seen by a Cardiologist in an Inova clinic or Inova hospital setting
- Left Ventricular Ejection Fraction ≤40%
Exclusion criteria
- Opted out of EHR-based research
- Hospice care
- Already receiving maximally titrated doses of each of the four classes of evidence- based HFrEF medical therapy
- Prior heart transplant
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Other
Study locations
United States · 1 center
- Inova Health System — Falls Church
Identifiers
NCT: NCT05433220 · U22-04-4736